OS Therapies CEO Paul Romness on OST-HER2, FDA Pathway & Biotech Growth | CEO Interview
Feb. 14, 2025
OS Therapies is a clinical-stage biopharmaceutical company pioneering innovative treatments for osteosarcoma (OS), HER2-positive cancers, and other solid tumors. With a focus on addressing unmet needs in pediatric and young adult oncology, the company’s lead candidate, OST-HER2, is a groundbreaking immunotherapy that has shown statistically significant improvements in 12-month event-free survival for recurrent, fully resected metastatic OS. OST-HER2 leverages a bioengineered Listeria monocytogenes strain to activate targeted immune responses, offering hope in an area where no new FDA-approved treatments have emerged in over 40 years.
Complementing OST-HER2, OS Therapies is advancing its next-generation Tunable Antibody Drug Conjugate (tADC) platform, powered by proprietary SiLinker™ technology. This innovative platform delivers precision-targeted payloads, creating opportunities to address challenging cancers such as ovarian, breast, and gastric tumors. By targeting high-impact areas within oncology, OS Therapies is positioned to deliver transformative solutions for patients with limited treatment options.
Visit www.redchip.com/stocks/OSTX to learn more.
